• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Health-Related Quality of Life in Patients With Schizophrenia During Treatment With Long-Acting, Injectable Risperidone.
【24h】

Health-Related Quality of Life in Patients With Schizophrenia During Treatment With Long-Acting, Injectable Risperidone.

机译：长效可注射利培酮治疗期间精神分裂症患者的健康相关生活质量。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We investigated the impact of treatment with long-acting, injectable risperidone versus placebo on health-related quality of life (HRQoL) in patients with schizophrenia. Results are discussed in the context of HRQoL in the general U.S. population. METHOD: Patients with DSM-IV schizophrenia entered a randomized, double-blind, placebo-controlled trial. After screening, previous antipsychotics were discontinued, and oral risperidone was titrated up to a dose of 4 mg/day over 1 week. Patients were then randomly assigned to receive placebo [N = 92] or long-acting risperidone (25 [N = 93], 50 [N = 97], or 75 mg [N = 87] every 2 weeks) for 12 weeks. HRQoL was measured using the Medical Outcomes Study Short-Form 36-item questionnaire (SF-36). RESULTS: At week 12, patients receiving long-acting risperidone had improved significantly (p <.05) in 5 domains of the SF-36 (bodily pain, general health, social functioning, role-emotional, and mental health) compared with patients receiving placebo. The effect was greatest for the 25-mg group, with significant improvement versus placebo in 6 domains (p <.05). At baseline, all SF-36 domain scores except bodily pain were significantly lower (p <.05) than normal values in all groups. With placebo, scores in all 8 domains remained below normal values after 12 weeks, while patients receiving long-acting risperidone showed improvement in HRQoL toward normal levels, with clinically meaningful improvements in all mental-health domains. In the 25-mg group, scores in 7 domains were not statistically different from normal values after 12 weeks. CONCLUSIONS: Long-acting, injectable risperidone improved HRQoL toward normal levels. After 12 weeks, HRQoL of patients receiving 25 mg was not significantly different from normal.
机译：背景：我们调查了长效，可注射利培酮和安慰剂治疗对精神分裂症患者健康相关生活质量（HRQoL）的影响。在美国一般人群的HRQoL中讨论了结果。方法：DSM-IV精神分裂症患者参加了一项随机，双盲，安慰剂对照试验。筛查后，停用先前的抗精神病药，并在1周内将口服利培酮调整至最高4 mg / day的剂量。然后将患者随机分配接受安慰剂[N = 92]或长效利培酮（每2周25 [N = 93]，50 [N = 97]或75 mg [N = 87]），持续12周。 HRQoL使用医学成果研究简短表格36项问卷（SF-36）进行测量。结果：与患者相比，接受长效利培酮治疗的患者在第12周时在SF-36的5个方面（身体疼痛，总体健康，社会功能，角色情感和心理健康）显着改善（p <.05）接受安慰剂。 25 mg组的效果最大，与安慰剂相比在6个域中有显着改善（p <.05）。在基线时，除身体疼痛外，所有组的所有SF-36域得分均显着低于正常值（p <.05）。使用安慰剂后，所有8个领域的得分在12周后仍低于正常值，而接受长效利培酮治疗的患者的HRQoL改善至正常水平，并且在所有心理健康领域均具有临床意义的改善。在25 mg组中，12周后7个域的得分与正常值无统计学差异。结论：长效可注射利培酮可将HRQoL提高至正常水平。 12周后，接受25 mg的患者的HRQoL与正常水平无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号